Many drugs, or their antecedents, were discovered through observation of their effects on
normal or disease physiology. For the past generation, this phenotypic drug discovery …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Parkinson disease (PD) is the most common neurodegenerative movement disorder. In
Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 …

Abstract The MDS Research Criteria for Prodromal PD allow the diagnosis of prodromal
Parkinson's disease using an evidence‐based conceptual framework, which was designed …

Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

We developed an endophenotype disease module-based methodology for Alzheimer's
disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier …

Parkinson's disease (PD) is one of the most common neurodegenerative disorders with a
global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both …

Parkinson's disease (PD) is a complex neurodegenerative disease with etiology rooted in
genetic vulnerability and environmental factors. Here we combine quantitative …

Parkinson disease (PD) treatment options have conventionally focused on dopamine
replacement and provision of symptomatic relief. Current treatments cause undesirable …

Neurodegenerative diseases are increasing in number, given that the general global
population is becoming older. They manifest themselves through mechanisms that are not …